Compare Alcon AG (ALC) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.91. The key difference: Alcon AG pays a 0.54% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals.
| ALC | SJNK | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Sector/Thematic |
52-Week High | $92.22 | $25.63 |
52-Week Low | $62.02 | $24.75 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SJNK trades at $24.97, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a consistent dividend schedule, with recent payouts of $0.14 and $0.15 per share. Recent news highlights institutional accumulation by firms like Berkshire Money Management, though analyst sentiment remains cautious due to high-yield bond market risks.
The outlook for SJNK is clouded by bearish technical indicators and concerns over the sustainability of high-yield bond performance. Risks include interest rate sensitivity and credit spread volatility, but steady dividends and institutional interest offer some support. Investors should weigh income stability against potential capital depreciation in a tightening credit environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
